Bio-Rad Laboratories Inc.
BIO | NYSE
$374.04
+$1.86 (+0.50%)
Nov 2, 2026, 10:32 AM ET · Market open
Market Data
Market Cap $10B
Enterprise Value $9.54B
Beta 1.07
Average Volume 272.81K
Shares Outstanding (Diluted) 26.81M
Shares Change YoY -1.52%
Institutional Ownership 73.30%
Exchange NYSE
ISIN US0905722072
Price Performance
Price Change 1M 1.3%
Price Change 3M 11.8%
Price Change 6M 45.1%
Price Change YTD 23.4%
Price Change 1Y 20.1%
Price Change 3Y 29.9%
Price Change 5Y -52.0%
1M CAGR (ann.) -1.1%
1Y CAGR (ann.) 16.5%
5Y CAGR (ann.) -13.2%
All-Time CAGR 8.9%
Valuation
PE Ratio 45.11
Forward PE 35.75
PEG Ratio -0.15
Forward PEG -12.31
PS Ratio 3.84
Forward PS 3.70
PB Ratio 1.39
P/FCF Ratio 28.18
P/Adj. FCF Ratio 32.38
P/OCF Ratio 20.21
EV/Sales 3.68
EV/EBIT 24.64
EV/EBITDA 17.84
EV/FCF 27.01
Earnings Yield 2.2%
FCF Yield 3.5%
Adj. FCF Yield 3.1%
Financial Health
Net Cash $414.8M
Total Debt $1.2B
Cash & Short-Term Investments $1.62B
Total Assets $10.25B
Current Ratio 3.14
Quick Ratio 2.33
Debt / Equity Ratio 0.17
Debt / EBITDA 2.25
Debt / FCF 3.41
OCF / Debt 0.41
Interest Coverage 6.40
Altman Z-Score 3.65
Piotroski F-Score 6
Margins & Profitability
Gross Profit Margin 51.9%
Operating Profit Margin 9.1%
EBITDA Margin 19.9%
Net Profit Margin 8.6%
FCF Margin 13.6%
Adj. FCF Margin 11.9%
SBC / Revenue 1.8%
SBC Impact (per share) -13.0%
Returns
Return on Assets 2.2%
Return on Equity 3.1%
Return on Invested Capital 1.5%
Return on Capital Employed 2.5%
Return on Tangible Assets 2.3%
Historical Growth (CAGR)
Revenue CAGR 3Y -2.2%
Revenue CAGR 5Y -2.1%
Revenue CAGR 10Y 2.5%
EPS CAGR 3Y 306.5%
EPS CAGR 5Y -42.8%
EPS CAGR 10Y 9.6%
FCF CAGR 3Y 32.2%
FCF CAGR 5Y -9.7%
FCF CAGR 10Y 16.3%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 3
EPS Growth Next 3Y 14.2%
Revenue Growth Next 3Y 2.9%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) $2.23
EPS Growth Est (next Q) -1.3%
Revenue Est (next Q) $649.94M
Revenue Growth Est (next Q) -0.5%
Fair Value Estimates
Graham Number $223.13
Graham Upside -40.0%
Lynch Fair Value $41.25
Lynch Upside -88.9%
Price Target $350.00
Price Target Upside -6.0%
Cash Flow
Operating Cash Flow $492.6M
Free Cash Flow $353.1M
Adj. Free Cash Flow $307.3M
FCF Per Share $13.20
OCF Per Share $18.42
OCF/S Ratio 19.0%
Income Statement
Revenue $2.59B
Gross Profit $1.34B
Operating Income $235M
EBITDA $534.6M
Net Income $222.4M
EPS (Diluted) $8.25
Revenue / Employee $347.56K
Profit / Employee $29.85K
Employees 7,450
Add to Watchlist
Select watchlists to add or remove BIO